Parion Sciences Announces Presentation of Clinical Data with Novel Pulmonary Delivery Device at the 2016 North American Cystic Fibrosis Conference

DURHAM, N.C., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced that an abstract from its pulmonary research and development efforts will be presented at the 30th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, Florida, October 27 through 29, 2016.

The accepted abstract is titled “PULMONARY AEROSOL DEPOSITION IN CHILDREN WITH CYSTIC FIBROSIS FOLLOWING TRANSNASAL DELIVERY OF HYPERTONIC SALINE” and is poster number 459. The poster will include deposition, safety, and tolerability data from the trial of a novel transnasal delivery device to deliver hypertonic saline to the lungs of children with Cystic Fibrosis. It will be presented on Thursday, October 27th between 11:15 am and 1:45 pm during the formal poster session.

The transnasal delivery device used in the study was developed and tested with the support of the Cystic Fibrosis Foundation.

About Parion Sciences

Parion Sciences is a development stage biopharmaceutical company dedicated to research, development and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the eye or airway. Parion has a diverse pipeline of pre-clinical and clinical candidates for the treatment of these diseases via distinctive mechanisms of action and approaches. Parion is at the forefront of ENaC development and is leveraging our scientific expertise in epithelial biology to expand our platforms and novel chemical compounds into new indications to treat mucosal defects. Parion has received support and grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation Therapeutics, Inc. For more information, please see our website at

Contact: Joe Schachle Chief Operating Officer (919)313-1194

Source: Parion Sciences